Join Us

October 2012 Research News

Save as Favorite
Sign in to receive recommendations (Learn more)

Paxil May Ease Hot Flashes
October 16, 2012

Two studies suggest that a low dose of the antidepressant medicine Paxil can lower the number and severity of hot flashes in some women. Read more...

Mammostrat Test Helps Estimate Recurrence Risk and Make Treatment Decisions
October 16, 2012

A study shows that the Mammostrat test can offer more information on the risk of early-stage, hormone-receptor-positive breast cancer coming back in postmenopausal women and help make treatment decisions. Read more...

Exercise, Counseling Can Help Ease Menopausal Symptoms Caused by Breast Cancer Treatment
October 13, 2012
A Dutch study has found that exercise and a type of counseling called cognitive behavioral therapy can help ease menopausal symptoms that often come during and after breast cancer treatment. Read more...

Fareston Is Effective Against Some Advanced-Stage Cancers That Have Stopped Responding to Aromatase Inhibitors
October 10, 2012

A small study has found that Fareston is a good treatment option for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive breast cancer that grew while being treated with the aromatase inhibitors Arimidex or Femara. Read more...

Memory Training Program Seems to Help Thinking and Remembering in Women Who’ve Been Treated for Breast Cancer
October 9, 2012

A small study has found that a computer-based training program improved the memories of women who’ve been treated for breast cancer, as well as their ability to quickly process information. Read more...

Needle Biopsy May Lead to Better Treatment Outcomes Than Open Biopsy
October 8, 2012

A study has found that diagnosing breast cancer with a needle biopsy instead of a traditional open surgical biopsy is more efficient, less invasive, and may lead to better treatment outcomes. Read more...

One Year of Herceptin Best for Reducing Recurrence Risk of Early-Stage HER2-Positive Disease
October 8, 2012

Results from two studies confirm that 1 year of Herceptin, rather than 2 years or 6 months, after surgery seems to be best for reducing recurrence risk in women diagnosed with HER2-positive early-stage breast cancer. Read more...

T-DM1 Lengthens Survival in Women Diagnosed with HER2-Positive Advanced-Stage Disease
October 3, 2012
Women diagnosed with HER2-positive advanced-stage breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen. Read more…

Was this article helpful? Yes / No
Rn icon

Can we help guide you?

Create a profile for better recommendations

How does this work? Learn more
Are these recommendations helpful? Take a quick survey

Fy22oct sidebarad v02
Back to Top